They don’t want to get stuck in the middle of a political issue on Bolar, which is what this may turn out to be.
Moreover, the FDA’s raison d’etre has never been to approve generic-drug applications as quickly and easily as possible. Such an assertion would be met by laughter if repeated to executives at TEVA, MYL, and WPI.
Market Data 
Markets 
AI
